Metformin and cancer: Technical and clinical implications for FDG-PET imaging

Area of Science:

• Oncology
• Pharmacology
• Nuclear Medicine

Background:

• Metformin is a widely prescribed hypoglycemic agent with emerging evidence supporting its anticancer properties.
• Potential anticancer mechanisms of metformin are independent of its glucose-lowering effects, involving cellular proliferation and glycolysis pathways.
• Numerous clinical trials are investigating metformin's efficacy in cancer treatment.

Purpose of the Study:

• To evaluate the potential interference of metformin with (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) imaging in cancer patients.
• To understand how metformin affects glucose handling and FDG distribution via pathways like AMP-activated protein kinase and Hexokinase.
• To provide guidance for interpreting FDG-PET scans in diabetic patients on metformin and in clinical trials of metformin as an anticancer therapy.

Main Methods:

• Review of existing literature on metformin's pharmacological actions and its impact on cellular metabolism.
• Analysis of potential mechanisms by which metformin could alter FDG uptake.
• Discussion of the implications for FDG-PET scan interpretation in the context of metformin use.

Main Results:

• Metformin's influence on AMP-activated protein kinase, insulin levels, and Hexokinase may alter glucose metabolism.
• These metabolic changes could potentially affect FDG distribution and PET scan results.
• Further research is needed to quantify this interference and its clinical significance.

Conclusions:

• A comprehensive understanding of metformin's impact on FDG uptake is crucial for accurate PET scan interpretation.
• This knowledge will aid in managing diabetic patients undergoing cancer evaluation and in interpreting results from metformin-based cancer clinical trials.
• Prospective data collection is necessary to determine if FDG-PET can effectively assess metformin's anticancer effects.